No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
NNVC240621C7500
- 0.00
- 0.000.00%
15min DelayClose Jun 14 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest7.50Strike Price0.00Turnover812.37%IV294.74%PremiumJun 21, 2024Expiry Date0.00Intrinsic Value100Multiplier5DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.2063Delta0.1459Gamma12.67Leverage Ratio-0.0463Theta0.0000Rho2.61Eff Leverage0.0007Vega
Intraday
- 5D
- 1D
No Data
News
Why AMMO Shares Are Trading Lower By Over 19%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of AMMO, Inc. (NASDAQ:POWW) fell sharply during Friday's session following fourth-quarter results.AMMO reported a fourth-quarter profit of 1 cent per share, compared to market expectations for
12 Health Care Stocks Moving In Friday's Intraday Session
GainersCyclerion Therapeutics (NASDAQ:CYCN) shares moved upwards by 37.4% to $2.9 during Friday's regular session. The market value of their outstanding shares is at $7.2 million. CNS Pharma (NASDAQ:C
12 Health Care Stocks Moving In Wednesday's Intraday Session
GainersLongeveron (NASDAQ:LGVN) shares rose 112.1% to $1.74 during Wednesday's regular session. The market value of their outstanding shares is at $11.0 million. vTv Therapeutics (NASDAQ:VTVT) stock i
Bullish Trend In NanoViricides (NNVC) Shares Following Promising Clinical Findings
Following the release of encouraging clinical trial data, shares of NanoViricides, Inc. (NYSE: NNVC) are demonstrating a bullish trend on US stock charts. As of the latest current-market check, NNVC stock increased by 7.92% to $3.27. Breakthrough Findings On NV-387 NanoViricides (NNVC) reported that its leading clinical-stage broad-spectrum antiviral drug candidate, NV-387, exhibits an ideal ...
Molecular MOLN Preclinical Data; NanoViricides NNVC Animal Model Data
Orally Administered NV-387 Results in Ideal Flat Blood Concentration Profile for Sustained Antiviral Effect
A First-In-Class, Broad-Spectrum Antiviral Agent Intending To Revolutionize Treatment of Viral Infections Including RSV, COVID, Influenzas and More SHELTON, CT / ACCESSWIRE / June 11, 2024 / NanoViricides, Inc. (NYSE
Comments
$Nanoviricides(NNVC.US$ Yes a beautiful uptrend overall since mid/late April. But more, very encouraging data for NV-387! A statement said a few months ago with results and data from early testing, that this could be the biggest thing in medicine since antibiotics. Well that would be amazing yes for stock price! But what that could mean for disease treatment overall could be a game changer? The early data seems that its still on that path.🤞❤️![]()
1
4
$Nanoviricides(NNVC.US$
The Sustained, Slow Declining, Blood Concentration Profile of NV-387 Enables Infrequent Dosing for Strong Antiviral Effect
NanoViricides announced a significant advancement in its lead antiviral agent, NV-387. This drug, designed for broad-spectrum antiviral treatment, has shown prolonged blood concentration levels in non-human primate models, indicating the potential for infrequent dosing. NV-387's unique polymeric design helps sustain drug levels, making it effecti...
The Sustained, Slow Declining, Blood Concentration Profile of NV-387 Enables Infrequent Dosing for Strong Antiviral Effect
NanoViricides announced a significant advancement in its lead antiviral agent, NV-387. This drug, designed for broad-spectrum antiviral treatment, has shown prolonged blood concentration levels in non-human primate models, indicating the potential for infrequent dosing. NV-387's unique polymeric design helps sustain drug levels, making it effecti...
4
$Nanoviricides(NNVC.US$
A First-In-Class, Broad-Spectrum Antiviral Agent Intending To Revolutionize Treatment of Viral Infections Including RSV, COVID, Influenzas and More
NanoViricides, a leader in broad-spectrum antiviral nanomedicines, has developed NV-387, a first-in-class antiviral agent targeting RSV, COVID-19, Influenza, and other viruses. NV-387 employs novel host-mimetic technology to remain effective despite viral mutations. It has outperformed existing drugs such as remdesivir, T...
A First-In-Class, Broad-Spectrum Antiviral Agent Intending To Revolutionize Treatment of Viral Infections Including RSV, COVID, Influenzas and More
NanoViricides, a leader in broad-spectrum antiviral nanomedicines, has developed NV-387, a first-in-class antiviral agent targeting RSV, COVID-19, Influenza, and other viruses. NV-387 employs novel host-mimetic technology to remain effective despite viral mutations. It has outperformed existing drugs such as remdesivir, T...
$Nanoviricides(NNVC.US$
NEWS
NanoViricides Bolsters Partnership Efforts - Engages Aagami Inc
NanoViricides has engaged Aagami Inc. to seek licensing and partnering opportunities for its key asset, NV-387, and platform technology in India and Japan. NV-387, a broad-spectrum antiviral nanomedicine, has completed Phase I clinical trials in healthy subjects with no adverse effects reported. It is now ready for Phase II trials.
NV-387, designed to mimic host-side virus-binding features, targets a wi...
NEWS
NanoViricides Bolsters Partnership Efforts - Engages Aagami Inc
NanoViricides has engaged Aagami Inc. to seek licensing and partnering opportunities for its key asset, NV-387, and platform technology in India and Japan. NV-387, a broad-spectrum antiviral nanomedicine, has completed Phase I clinical trials in healthy subjects with no adverse effects reported. It is now ready for Phase II trials.
NV-387, designed to mimic host-side virus-binding features, targets a wi...
1
2
Read more
72991267 : Could this get to 1 Bil Market Cap? If it’s used for multiple types of infections around the world, then I don’t see why not.
TrytosaveabitOP 72991267: It’s still early in testing but very encouraging! I’m actually using it in my long hold account as well! IMO if the data keeps going the way it is as more testing is done. The company will see big things. Not to mention it turns ( IMO ) into a very strong buyout candidate from one of the huge players in the bio space? NFA! GL and big profits to ya!
Tonyco : yeah, this shit is fire. It copies the mechanisms viruses use to infect human cells to fool the virus into infecting the Nanoviricide instead. Even with mutations, because they still use that same chemical marker.
LT holder for sure. Good buy dip today. With a drop and no news I can only assume ppl be taking profit, since it's been on a run for weeks
TrytosaveabitOP Tonyco: Very nicely said! I agree, this is one of the rare longer holds for me! I will see what Monday brings? If it starts consolidating? I may scale in a bit more! Thanks for sharing! GL and have a great weekend!